Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Cardiovascular Risk in Rheumatoid Arthritis and Mechanistic Links: From Pathophysiology to Treatment

Author(s): George E. Fragoulis*, Ismini Panayotidis and Elena Nikiphorou

Volume 18, Issue 5, 2020

Page: [431 - 446] Pages: 16

DOI: 10.2174/1570161117666190619143842

Price: $65

Abstract

Rheumatoid arthritis (RA) is an autoimmune inflammatory arthritis. Inflammation, however, can spread beyond the joints to involve other organs. During the past few years, it has been well recognized that RA associates with increased risk for cardiovascular (CV) disease (CVD) compared with the general population. This seems to be due not only to the increased occurrence in RA of classical CVD risk factors and comorbidities like smoking, obesity, hypertension, diabetes, metabolic syndrome, and others but also to the inflammatory burden that RA itself carries. This is not unexpected given the strong links between inflammation and atherosclerosis and CVD. It has been shown that inflammatory cytokines which are present in abundance in RA play a significant role in every step of plaque formation and rupture. Most of the therapeutic regimes used in RA treatment seem to offer significant benefits to that end. However, more studies are needed to clarify the effect of these drugs on various parameters, including the lipid profile. Of note, although pharmacological intervention significantly helps reduce the inflammatory burden and therefore the CVD risk, control of the so-called classical risk factors is equally important. Herein, we review the current evidence for the underlying pathogenic mechanisms linking inflammation with CVD in the context of RA and reflect on the possible impact of treatments used in RA.

Keywords: Rheumatoid arthritis, cardiovascular disease, atherosclerosis, hypertension, diabetes, metabolic syndrome.

« Previous Next »
Graphical Abstract

[1]
Urman A, Taklalsingh N, Sorrento C, McFarlane IM. Inflammation beyond the Joints: rheumatoid arthritis and cardiovascular disease. Scifed J Cardiol 2018; 2(3) 1000019
[PMID: 30607397]
[2]
Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012; 71(9): 1524-9.
[http://dx.doi.org/10.1136/annrheumdis-2011-200726] [PMID: 22425941]
[3]
Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107(9): 1303-7.
[http://dx.doi.org/10.1161/01.CIR.0000054612.26458.B2] [PMID: 12628952]
[4]
Gabriel SE, Crowson CS, Kremers HM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003; 48(1): 54-8.
[http://dx.doi.org/10.1002/art.10705] [PMID: 12528103]
[5]
Gonzalez A, Maradit Kremers H, Crowson CS, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007; 56(11): 3583-7.
[http://dx.doi.org/10.1002/art.22979] [PMID: 17968923]
[6]
Poppelaars PBM, van Tuyl LHD, Boers M. Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up. Ann Rheum Dis 2019; 78(5): 586-9.
[http://dx.doi.org/10.1136/annrheumdis-2018-214618] [PMID: 30808623]
[7]
Myasoedova E, Gabriel SE, Matteson EL, Davis JM III, Therneau TM, Crowson CS. Decreased cardiovascular mortality in patients with incident rheumatoid arthritis (RA) in recent years: dawn of a new era in cardiovascular disease in RA? J Rheumatol 2017; 44(6): 732-9.
[http://dx.doi.org/10.3899/jrheum.161154] [PMID: 28365576]
[8]
Burggraaf B, van Breukelen-van der Stoep DF, de Vries MA, et al. Effect of a treat-to-target intervention of cardiovascular risk factors on subclinical and clinical atherosclerosis in rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis 2019; 78(3): 335-41.
[http://dx.doi.org/10.1136/annrheumdis-2018-214075] [PMID: 30610067]
[9]
Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342(12): 836-43.
[http://dx.doi.org/10.1056/NEJM200003233421202] [PMID: 10733371]
[10]
Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32(9): 2045-51.
[http://dx.doi.org/10.1161/ATVBAHA.108.179705] [PMID: 22895665]
[11]
McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007; 7(6): 429-42.
[http://dx.doi.org/10.1038/nri2094] [PMID: 17525752]
[12]
Taleb S, Tedgui A, Mallat Z. IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles. Arterioscler Thromb Vasc Biol 2015; 35(2): 258-64.
[http://dx.doi.org/10.1161/ATVBAHA.114.303567] [PMID: 25234818]
[13]
Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108(24): 2957-63.
[http://dx.doi.org/10.1161/01.CIR.0000099844.31524.05] [PMID: 14676136]
[14]
Skeoch S, Bruce IN. Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol 2015; 11(7): 390-400.
[http://dx.doi.org/10.1038/nrrheum.2015.40] [PMID: 25825281]
[15]
Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99(24): 3092-5.
[http://dx.doi.org/10.1161/01.CIR.99.24.3092] [PMID: 10377069]
[16]
Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet 1997; 349(9062): 1391-2.
[http://dx.doi.org/10.1016/S0140-6736(96)09424-X] [PMID: 9149715]
[17]
Chia S, Qadan M, Newton R, Ludlam CA, Fox KA, Newby DE. Intra-arterial tumor necrosis factor-alpha impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans. Arterioscler Thromb Vasc Biol 2003; 23(4): 695-701.
[http://dx.doi.org/10.1161/01.ATV.0000065195.22904.FA] [PMID: 12692009]
[18]
Zhu F, Wang Q, Guo C, et al. IL-17 induces apoptosis of vascular endothelial cells: a potential mechanism for human acute coronary syndrome. Clin Immunol 2011; 141(2): 152-60.
[http://dx.doi.org/10.1016/j.clim.2011.07.003] [PMID: 21872532]
[19]
Mahmoudi M, Aslani S, Fadaei R, Jamshidi AR. New insights to the mechanisms underlying atherosclerosis in rheumatoid arthritis. Int J Rheum Dis 2017; 20(3): 287-97.
[http://dx.doi.org/10.1111/1756-185X.12999] [PMID: 28205331]
[20]
Lei L, Xiong Y, Chen J, et al. TNF-alpha stimulates the ACAT1 expression in differentiating monocytes to promote the CE-laden cell formation. J Lipid Res 2009; 50(6): 1057-67.
[http://dx.doi.org/10.1194/jlr.M800484-JLR200] [PMID: 19189937]
[21]
Singh SK, Suresh MV, Prayther DC, Moorman JP, Rusiñol AE, Agrawal A. C-reactive protein-bound enzymatically modified low-density lipoprotein does not transform macrophages into foam cells. J Immunol 2008; 180(6): 4316-22.
[http://dx.doi.org/10.4049/jimmunol.180.6.4316] [PMID: 18322245]
[22]
Wang X, Liao D, Bharadwaj U, Li M, Yao Q, Chen C. C-reactive protein inhibits cholesterol efflux from human macrophage-derived foam cells. Arterioscler Thromb Vasc Biol 2008; 28(3): 519-26.
[http://dx.doi.org/10.1161/ATVBAHA.107.159467] [PMID: 18096828]
[23]
Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol 2015; 15(2): 104-16.
[http://dx.doi.org/10.1038/nri3793] [PMID: 25614320]
[24]
Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol 2010; 30(7): 1282-92.
[http://dx.doi.org/10.1161/ATVBAHA.108.179739] [PMID: 20554950]
[25]
Singh U, Dasu MR, Yancey PG, Afify A, Devaraj S, Jialal I. Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats. J Lipid Res 2008; 49(5): 1015-23.
[http://dx.doi.org/10.1194/jlr.M700535-JLR200] [PMID: 18245817]
[26]
Mackey RH, Kuller LH, Deane KD, et al. Rheumatoid arthritis, anti-cyclic citrullinated peptide positivity, and cardiovascular disease risk in the women’s health initiative. Arthritis Rheumatol 2015; 67(9): 2311-22.
[http://dx.doi.org/10.1002/art.39198] [PMID: 25988241]
[27]
Rho YH, Chung CP, Oeser A, et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2009; 61(11): 1580-5.
[http://dx.doi.org/10.1002/art.25009] [PMID: 19877084]
[28]
Dessein PH, Joffe BI, Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2005; 7(3): R634-43.
[http://dx.doi.org/10.1186/ar1717] [PMID: 15899050]
[29]
Koch AE, Kunkel SL, Harlow LA, et al. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 1992; 90(3): 772-9.
[http://dx.doi.org/10.1172/JCI115950] [PMID: 1522232]
[30]
Navarro-Hernández RE, Oregon-Romero E, Vázquez-Del Mercado M, Rangel-Villalobos H, Palafox-Sánchez CA, Muñoz-Valle JF. Expression of ICAM1 and VCAM1 serum levels in rheumatoid arthritis clinical activity. Association with genetic polymorphisms. Dis Markers 2009; 26(3): 119-26.
[http://dx.doi.org/10.1155/2009/510104] [PMID: 19597294]
[31]
Giles JT, Post WS, Blumenthal RS, et al. Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2011; 63(11): 3216-25.
[http://dx.doi.org/10.1002/art.30542] [PMID: 21965129]
[32]
Nagata-Sakurai M, Inaba M, Goto H, et al. Inflammation and bone resorption as independent factors of accelerated arterial wall thickening in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48(11): 3061-7.
[http://dx.doi.org/10.1002/art.11327] [PMID: 14613267]
[33]
Karpouzas GA, Malpeso J, Choi TY, Li D, Munoz S, Budoff MJ. Prevalence, extent and composition of coronary plaque in patients with rheumatoid arthritis without symptoms or prior diagnosis of coronary artery disease. Ann Rheum Dis 2014; 73(10): 1797-804.
[http://dx.doi.org/10.1136/annrheumdis-2013-203617] [PMID: 23887286]
[34]
Aubry MC, Maradit-Kremers H, Reinalda MS, Crowson CS, Edwards WD, Gabriel SE. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol 2007; 34(5): 937-42.
[PMID: 17361987]
[35]
Semb AG, Rollefstad S, Provan SA, et al. Carotid plaque characteristics and disease activity in rheumatoid arthritis. J Rheumatol 2013; 40(4): 359-68.
[http://dx.doi.org/10.3899/jrheum.120621] [PMID: 23322468]
[36]
van Sijl AM, Peters MJ, Knol DK, et al. Carotid intima media thickness in rheumatoid arthritis as compared to control subjects: a meta-analysis. Semin Arthritis Rheum 2011; 40(5): 389-97.
[http://dx.doi.org/10.1016/j.semarthrit.2010.06.006] [PMID: 20889191]
[37]
Hannawi S, Haluska B, Marwick TH, Thomas R. Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation. Arthritis Res Ther 2007; 9(6): R116.
[http://dx.doi.org/10.1186/ar2323] [PMID: 17986352]
[38]
Södergren A, Karp K, Boman K, et al. Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. Arthritis Res Ther 2010; 12(4): R158.
[http://dx.doi.org/10.1186/ar3116] [PMID: 20712865]
[39]
Lo Gullo A, Rodríguez-Carrio J, Aragona CO, et al. Subclinical impairment of myocardial and endothelial functionality in very early psoriatic and rheumatoid arthritis patients: Association with vitamin D and inflammation. Atherosclerosis 2018; 271: 214-22.
[http://dx.doi.org/10.1016/j.atherosclerosis.2018.03.004] [PMID: 29524864]
[40]
Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 2005; 52(8): 2293-9.
[http://dx.doi.org/10.1002/art.21204] [PMID: 16052597]
[41]
Innala L, Möller B, Ljung L, et al. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther 2011; 13(4): R131.
[http://dx.doi.org/10.1186/ar3442] [PMID: 21843325]
[42]
Mantel Ä, Holmqvist M, Nyberg F, et al. Risk factors for the rapid increase in risk of acute coronary events in patients with new-onset rheumatoid arthritis: a nested case-control study. Arthritis Rheumatol 2015; 67(11): 2845-54.
[http://dx.doi.org/10.1002/art.39267] [PMID: 26138387]
[43]
Arts EE, Fransen J, den Broeder AA, Popa CD, van Riel PL. The effect of disease duration and disease activity on the risk of cardio-vascular disease in rheumatoid arthritis patients. Ann Rheum Dis 2015; 74(6): 998-1003.
[http://dx.doi.org/10.1136/annrheumdis-2013-204531] [PMID: 24458537]
[44]
Zhang J, Chen L, Delzell E, et al. The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis 2014; 73(7): 1301-8.
[http://dx.doi.org/10.1136/annrheumdis-2013-204715] [PMID: 24796336]
[45]
Solomon DH, Reed GW, Kremer JM, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol 2015; 67(6): 1449-55.
[http://dx.doi.org/10.1002/art.39098] [PMID: 25776112]
[46]
Myasoedova E, Chandran A, Ilhan B, et al. The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease. Ann Rheum Dis 2016; 75(3): 560-5.
[http://dx.doi.org/10.1136/annrheumdis-2014-206411] [PMID: 25637001]
[47]
Crowson CS, Rollefstad S, Ikdahl E, et al. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis 2018; 77(1): 48-54.
[http://dx.doi.org/10.1136/annrheumdis-2017-211735] [PMID: 28877868]
[48]
Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DP. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002; 46(8): 2010-9.
[http://dx.doi.org/10.1002/art.10419] [PMID: 12209502]
[49]
Tomasson G, Aspelund T, Jonsson T, Valdimarsson H, Felson DT, Gudnason V. Effect of rheumatoid factor on mortality and coronary heart disease. Ann Rheum Dis 2010; 69(9): 1649-54.
[http://dx.doi.org/10.1136/ard.2009.110536] [PMID: 19628821]
[50]
Solomon DH, Greenberg J, Curtis JR, et al. Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a Consortium of rheumatology researchers of North America registry study. Arthritis Rheumatol 2015; 67(8): 1995-2003.
[http://dx.doi.org/10.1002/art.39195] [PMID: 25989470]
[51]
Montes A, Corrales A, Calaza M, et al. Brief report: lack of replication of an association between anti-citrullinated fibrinogen and subclinical atherosclerosis in patients with rheumatoid arthritis. Arthritis Rheumatol 2015; 67(11): 2861-5.
[http://dx.doi.org/10.1002/art.39302] [PMID: 26246227]
[52]
Sokolove J, Brennan MJ, Sharpe O, et al. Brief report: citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis. Arthritis Rheum 2013; 65(7): 1719-24.
[http://dx.doi.org/10.1002/art.37961] [PMID: 23553485]
[53]
Cambridge G, Acharya J, Cooper JA, Edwards JC, Humphries SE. Antibodies to citrullinated peptides and risk of coronary heart disease. Atherosclerosis 2013; 228(1): 243-6.
[http://dx.doi.org/10.1016/j.atherosclerosis.2013.02.009] [PMID: 23474125]
[54]
Humphreys JH, van Nies JA, Chipping J, et al. Rheumatoid factor and anti-citrullinated protein antibody positivity, but not level, are associated with increased mortality in patients with rheumatoid arthritis: results from two large independent cohorts. Arthritis Res Ther 2014; 16(6): 483.
[http://dx.doi.org/10.1186/s13075-014-0483-3] [PMID: 25471696]
[55]
López-Longo FJ, Oliver-Miñarro D, de la Torre I, et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum 2009; 61(4): 419-24.
[http://dx.doi.org/10.1002/art.24390] [PMID: 19333979]
[56]
Baghdadi LR, Woodman RJ, Shanahan EM, Mangoni AA. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS One 2015; 10(2)e0117952
[http://dx.doi.org/10.1371/journal.pone.0117952] [PMID: 25689371]
[57]
Boyer JF, Gourraud PA, Cantagrel A, Davignon JL, Constantin A. Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine 2011; 78(2): 179-83.
[http://dx.doi.org/10.1016/j.jbspin.2010.07.016] [PMID: 20851020]
[58]
Naranjo A, Sokka T, Descalzo MA, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008; 10(2): R30.
[http://dx.doi.org/10.1186/ar2383] [PMID: 18325087]
[59]
Jiang P, Li H, Li X. Diabetes mellitus risk factors in rheumatoid arthritis: a systematic review and meta-analysis. Clin Exp Rheumatol 2015; 33(1): 115-21.
[PMID: 25535750]
[60]
Solomon DH, Love TJ, Canning C, Schneeweiss S. Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and pso-riasis. Ann Rheum Dis 2010; 69(12): 2114-7.
[http://dx.doi.org/10.1136/ard.2009.125476] [PMID: 20584807]
[61]
Barbhaiya M, Solomon DH. Rheumatoid arthritis and cardiovascular disease: an update on treatment issues. Curr Opin Rheumatol 2013; 25(3): 317-24.
[http://dx.doi.org/10.1097/BOR.0b013e32835fd7f8] [PMID: 23466960]
[62]
Dessein PH, Joffe BI, Stanwix AE. Inflammation, insulin resistance, and aberrant lipid metabolism as cardiovascular risk factors in rheumatoid arthritis. J Rheumatol 2003; 30(7): 1403-5.
[PMID: 12858433]
[63]
Giles JT, Danielides S, Szklo M, et al. Insulin resistance in rheumatoid arthritis: disease-related indicators and associations with the presence and progression of subclinical atherosclerosis. Arthritis Rheumatol 2015; 67(3): 626-36.
[http://dx.doi.org/10.1002/art.38986] [PMID: 25504899]
[64]
Chung CP, Oeser A, Solus JF, et al. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 2008; 58(7): 2105-12.
[http://dx.doi.org/10.1002/art.23600] [PMID: 18576352]
[65]
La Montagna G, Cacciapuoti F, Buono R, et al. Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritis. Diab Vasc Dis Res 2007; 4(2): 130-5.
[http://dx.doi.org/10.3132/dvdr.2007.031] [PMID: 17654447]
[66]
Söderlin MK, Petersson IF, Geborek P. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. Scand J Rheumatol 2012; 41(1): 1-9.
[http://dx.doi.org/10.3109/03009742.2011.599073] [PMID: 22118371]
[67]
Lee YH, Bae SC, Song GG. Gene-environmental interaction between smoking and shared epitope on the development of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: a meta-analysis. Int J Rheum Dis 2014; 17(5): 528-35.
[http://dx.doi.org/10.1111/1756-185X.12307] [PMID: 24618101]
[68]
Chung CP, Giles JT, Petri M, et al. Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the multi-ethnic study of atherosclerosis. Semin Arthritis Rheum 2012; 41(4): 535-44.
[http://dx.doi.org/10.1016/j.semarthrit.2011.07.004] [PMID: 22340996]
[69]
Chung CP, Oeser A, Solus JF, et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008; 196(2): 756-63.
[http://dx.doi.org/10.1016/j.atherosclerosis.2007.01.004] [PMID: 17266963]
[70]
Panoulas VF, Metsios GS, Pace AV, et al. Hypertension in rheumatoid arthritis. Rheumatology (Oxford) 2008; 47(9): 1286-98.
[http://dx.doi.org/10.1093/rheumatology/ken159] [PMID: 18467370]
[71]
Protogerou AD, Panagiotakos DB, Zampeli E, et al. Arterial hypertension assessed “out-of-office” in a contemporary cohort of rheumatoid arthritis patients free of cardiovascular disease is characterized by high prevalence, low awareness, poor control and increased vascular damage-associated “white coat” phenomenon. Arthritis Res Ther 2013; 15(5): R142.
[http://dx.doi.org/10.1186/ar4324] [PMID: 24286134]
[72]
Dessein PH, Joffe BI, Veller MG, et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 2005; 32(3): 435-42.
[PMID: 15742434]
[73]
Curtis JR, John A, Baser O. Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken) 2012; 64(9): 1282-91.
[http://dx.doi.org/10.1002/acr.21693] [PMID: 22504829]
[74]
Toms TE, Panoulas VF, Douglas KM, et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? Ann Rheum Dis 2010; 69(4): 683-8.
[http://dx.doi.org/10.1136/ard.2009.115717] [PMID: 19854705]
[75]
Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011; 70(3): 482-7.
[http://dx.doi.org/10.1136/ard.2010.135871] [PMID: 21216812]
[76]
Lee YH, Choi SJ, Ji JD, Seo HS, Song GG. Lipoprotein(a) and lipids in relation to inflammation in rheumatoid arthritis. Clin Rheumatol 2000; 19(4): 324-5.
[http://dx.doi.org/10.1007/PL00011174] [PMID: 10941819]
[77]
Watanabe J, Charles-Schoeman C, Miao Y, et al. Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum 2012; 64(6): 1828-37.
[http://dx.doi.org/10.1002/art.34363] [PMID: 22231638]
[78]
McInnes IB, McCarey DW, Sattar N. Do statins offer therapeutic potential in inflammatory arthritis? Ann Rheum Dis 2004; 63(12): 1535-7.
[http://dx.doi.org/10.1136/ard.2004.022061] [PMID: 15547075]
[79]
Soulaidopoulos S, Nikiphorou E, Dimitroulas T, Kitas GD. The role of statins in disease modification and cardiovascular risk in rheuma-toid arthritis. Front Med (Lausanne) 2018; 5: 24.
[http://dx.doi.org/10.3389/fmed.2018.00024] [PMID: 29473041]
[80]
Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017; 76(1): 17-28.
[http://dx.doi.org/10.1136/annrheumdis-2016-209775] [PMID: 27697765]
[81]
McCarey DW, McInnes IB, Madhok R, et al. Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004; 363(9426): 2015-21.
[http://dx.doi.org/10.1016/S0140-6736(04)16449-0] [PMID: 15207950]
[82]
Kitas GD, Nightingale P, Armitage J, Sattar N, Belch JJF, Symmons DPM. Trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis (TRACE RA): A multicenter, randomized, placebo controlled trial. Arthritis Rheumatol 2019; 71(9): 1437-49.
[http://dx.doi.org/10.1002/art.40892]
[83]
Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670-81.
[http://dx.doi.org/10.1016/S0140-6736(10)61350-5] [PMID: 21067804]
[84]
Sheng X, Murphy MJ, Macdonald TM, Wei L. Effectiveness of statins on total cholesterol and cardiovascular disease and all-cause mortality in osteoarthritis and rheumatoid arthritis. J Rheumatol 2012; 39(1): 32-40.
[http://dx.doi.org/10.3899/jrheum.110318] [PMID: 22045835]
[85]
Rollefstad S, Ikdahl E, Hisdal J, et al. Rosuvastatin-induced carotid plaque regression in patients with inflammatory joint diseases: the rosuvastatin in rheumatoid arthritis, ankylosing spondylitis and other inflammatory joint diseases study. Arthritis Rheumatol 2015; 67(7): 1718-28.
[http://dx.doi.org/10.1002/art.39114] [PMID: 25778850]
[86]
Semb AG, Holme I, Kvien TK, Pedersen TR. Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial. Rheumatology (Oxford) 2011; 50(2): 324-9.
[http://dx.doi.org/10.1093/rheumatology/keq295] [PMID: 20884656]
[87]
de Hair MJ, Landewé RB, van de Sande MG, et al. Smoking and overweight determine the likelihood of developing rheumatoid arthritis. Ann Rheum Dis 2013; 72(10): 1654-8.
[http://dx.doi.org/10.1136/annrheumdis-2012-202254] [PMID: 23104761]
[88]
Lu B, Hiraki LT, Sparks JA, et al. Being overweight or obese and risk of developing rheumatoid arthritis among women: a prospective cohort study. Ann Rheum Dis 2014; 73(11): 1914-22.
[http://dx.doi.org/10.1136/annrheumdis-2014-205459] [PMID: 25057178]
[89]
Ajeganova S, Andersson ML, Hafström I, Group BS. Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term follow up from disease onset. Arthritis Care Res (Hoboken) 2013; 65(1): 78-87.
[http://dx.doi.org/10.1002/acr.21710] [PMID: 22514159]
[90]
Finckh A, Turesson C. The impact of obesity on the development and progression of rheumatoid arthritis. Ann Rheum Dis 2014; 73(11): 1911-3.
[http://dx.doi.org/10.1136/annrheumdis-2014-205741] [PMID: 25288687]
[91]
Nikiphorou E, Norton S, Young A, et al. The association of obesity with disease activity, functional ability and quality of life in early rheumatoid arthritis: data from the early rheumatoid arthritis study/early rheumatoid arthritis network UK prospective cohorts. Rheumatology (Oxford) 2018; 57(7): 1194-202.
[http://dx.doi.org/10.1093/rheumatology/key066] [PMID: 29590474]
[92]
Westhoff G, Rau R, Zink A. Radiographic joint damage in early rheumatoid arthritis is highly dependent on body mass index. Arthritis Rheum 2007; 56(11): 3575-82.
[http://dx.doi.org/10.1002/art.23033] [PMID: 17968909]
[93]
Levitsky A, Brismar K, Hafström I, et al. Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial. RMD Open 2017; 3(2) e000458
[http://dx.doi.org/10.1136/rmdopen-2017-000458] [PMID: 28879052]
[94]
Nikiphorou E, Fragoulis GE. Inflammation, obesity and rheumatic disease: common mechanistic links. A narrative review. Ther Adv Musculoskelet Dis 2018; 10(8): 157-67.
[http://dx.doi.org/10.1177/1759720X18783894] [PMID: 30181786]
[95]
Rajbhandary R, Khezri A, Panush RS. Rheumatoid cachexia: what is it and why is it important? J Rheumatol 2011; 38(3): 406-8.
[http://dx.doi.org/10.3899/jrheum.101036] [PMID: 21362777]
[96]
Walsmith J, Roubenoff R. Cachexia in rheumatoid arthritis. Int J Cardiol 2002; 85(1): 89-99.
[http://dx.doi.org/10.1016/S0167-5273(02)00237-1] [PMID: 12163213]
[97]
Giles JT, Allison M, Blumenthal RS, et al. Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum 2010; 62(11): 3173-82.
[http://dx.doi.org/10.1002/art.27629] [PMID: 20589684]
[98]
Escalante A, Haas RW, del Rincón I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 2005; 165(14): 1624-9.
[http://dx.doi.org/10.1001/archinte.165.14.1624] [PMID: 16043681]
[99]
Kremers HM, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Prognostic importance of low body mass index in relation to cardi-ovascular mortality in rheumatoid arthritis. Arthritis Rheum 2004; 50(11): 3450-7.
[http://dx.doi.org/10.1002/art.20612] [PMID: 15529378]
[100]
Gremese E, Tolusso B, Gigante MR, Ferraccioli G. Obesity as a risk and severity factor in rheumatic diseases (autoimmune chronic inflammatory diseases). Front Immunol 2014; 5: 576.
[http://dx.doi.org/10.3389/fimmu.2014.00576] [PMID: 25426122]
[101]
Cao H, Lin J, Chen W, Xu G, Sun C. Baseline adiponectin and leptin levels in predicting an increased risk of disease activity in rheumatoid arthritis: A meta-analysis and systematic review. Autoimmunity 2016; 49(8): 547-53.
[http://dx.doi.org/10.1080/08916934.2016.1230847] [PMID: 27690205]
[102]
Gonzalez-Gay MA, Garcia-Unzueta MT, Berja A, et al. Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis. Clin Exp Rheumatol 2009; 27(2): 222-8.
[PMID: 19473561]
[103]
Härle P, Sarzi-Puttini P, Cutolo M, Straub RH. No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65(7): 970-1.
[http://dx.doi.org/10.1136/ard.2005.040857] [PMID: 16769786]
[104]
Popa C, Netea MG, de Graaf J, et al. Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis. J Rheumatol 2009; 36(4): 724-30.
[http://dx.doi.org/10.3899/jrheum.080626] [PMID: 19273452]
[105]
Choi HM, Lee YA, Lee SH, et al. Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than proinflammatory mediators. Arthritis Res Ther 2009; 11(6): R161.
[http://dx.doi.org/10.1186/ar2844] [PMID: 19883500]
[106]
Frommer KW, Zimmermann B, Meier FM, et al. Adiponectin-mediated changes in effector cells involved in the pathophysiology of rheumatoid arthritis. Arthritis Rheum 2010; 62(10): 2886-99.
[http://dx.doi.org/10.1002/art.27616] [PMID: 20564003]
[107]
Qian J, Xu L, Sun X, et al. Adiponectin aggravates bone erosion by promoting osteopontin production in synovial tissue of rheumatoid arthritis. Arthritis Res Ther 2018; 20(1): 26.
[http://dx.doi.org/10.1186/s13075-018-1526-y] [PMID: 29422077]
[108]
Giles JT, van der Heijde DM, Bathon JM. Association of circulating adiponectin levels with progression of radiographic joint destruction in rheumatoid arthritis. Ann Rheum Dis 2011; 70(9): 1562-8.
[http://dx.doi.org/10.1136/ard.2011.150813] [PMID: 21571734]
[109]
Lee YH, Bae SC. Circulating adiponectin and visfatin levels in rheumatoid arthritis and their correlation with disease activity: A meta-analysis. Int J Rheum Dis 2018; 21(3): 664-72.
[http://dx.doi.org/10.1111/1756-185X.13038] [PMID: 28205390]
[110]
Sato H, Muraoka S, Kusunoki N, et al. Resistin upregulates chemokine production by fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Res Ther 2017; 19(1): 263.
[http://dx.doi.org/10.1186/s13075-017-1472-0] [PMID: 29191223]
[111]
Otero M, Lago R, Gomez R, et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65(9): 1198-201.
[http://dx.doi.org/10.1136/ard.2005.046540] [PMID: 16414972]
[112]
Rho YH, Solus J, Sokka T, et al. Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum 2009; 60(7): 1906-14.
[http://dx.doi.org/10.1002/art.24626] [PMID: 19565493]
[113]
Weijers JM, Rongen-van Dartel SAA, Hoevenaars DMGMF, Rubens M, Hulscher MEJL, van Riel PLCM. Implementation of the EULAR cardiovascular risk management guideline in patients with rheumatoid arthritis: results of a successful collaboration between primary and secondary care. Ann Rheum Dis 2018; 77(4): 480-3.
[http://dx.doi.org/10.1136/annrheumdis-2017-212392] [PMID: 29167154]
[114]
Sglunda O, Mann H, Hulejová H, et al. Decreased circulating visfatin is associated with improved disease activity in early rheumatoid arthritis: data from the PERAC cohort. PLoS One 2014; 9(7)e103495
[http://dx.doi.org/10.1371/journal.pone.0103495] [PMID: 25068448]
[115]
Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, et al. HLA-DRB1 and persistent chronic inflammation contribute to car-diovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57(1): 125-32.
[http://dx.doi.org/10.1002/art.22482] [PMID: 17266100]
[116]
Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, et al. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 2003; 114(8): 647-52.
[http://dx.doi.org/10.1016/S0002-9343(03)00133-5] [PMID: 12798452]
[117]
Palomino-Morales R, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, et al. Interleukin-6 gene -174 promoter polymorphism is associated with endothelial dysfunction but not with disease susceptibility in patients with rheumatoid arthritis. Clin Exp Rheumatol 2009; 27(6): 964-70.
[PMID: 20149313]
[118]
Palomino-Morales R, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, et al. A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis. Arthritis Res Ther 2010; 12(2): R71.
[http://dx.doi.org/10.1186/ar2989] [PMID: 20423475]
[119]
Panoulas VF, Stavropoulos-Kalinoglou A, Metsios GS, et al. Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. Atherosclerosis 2009; 204(1): 178-83.
[http://dx.doi.org/10.1016/j.atherosclerosis.2008.08.036] [PMID: 18848327]
[120]
Panoulas VF, Douglas KM, Smith JP, et al. Transforming growth factor-beta1 869T/C, but not interleukin-6 -174G/C, polymorphism associates with hypertension in rheumatoid arthritis. Rheumatology (Oxford) 2009; 48(2): 113-8.
[http://dx.doi.org/10.1093/rheumatology/ken443] [PMID: 19106168]
[121]
Panoulas VF, Douglas KM, Smith JP, et al. Polymorphisms of the endothelin-1 gene associate with hypertension in patients with rheumatoid arthritis. Endothelium 2008; 15(4): 203-12.
[http://dx.doi.org/10.1080/10623320802228708] [PMID: 18663623]
[122]
Lindhardsen J, Gislason GH, Jacobsen S, et al. Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis 2014; 73(8): 1515-21.
[http://dx.doi.org/10.1136/annrheumdis-2012-203137] [PMID: 23749610]
[123]
Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74(3): 480-9.
[http://dx.doi.org/10.1136/annrheumdis-2014-206624] [PMID: 25561362]
[124]
Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121(4): 289-300.
[http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00011] [PMID: 8037411]
[125]
Sriperumbuduri S, Hiremath S. The case for cautious consumption: NSAIDs in chronic kidney disease. Curr Opin Nephrol Hypertens 2019; 28(2): 163-70.
[http://dx.doi.org/10.1097/MNH.0000000000000473] [PMID: 30531470]
[126]
Aviña-Zubieta JA, Abrahamowicz M, De Vera MA, et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology (Oxford) 2013; 52(1): 68-75.
[http://dx.doi.org/10.1093/rheumatology/kes353] [PMID: 23192907]
[127]
del Rincón I, Battafarano DF, Restrepo JF, Erikson JM, Escalante A. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol 2014; 66(2): 264-72.
[http://dx.doi.org/10.1002/art.38210] [PMID: 24504798]
[128]
Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, González-González JG, Tamez-Peña AL. Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review. World J Diabetes 2015; 6(8): 1073-81.
[http://dx.doi.org/10.4239/wjd.v6.i8.1073] [PMID: 26240704]
[129]
Rasch LA, Bultink IE, van Tuyl LH, Lems WF. Glucocorticoid safety for treating rheumatoid arthritis. Expert Opin Drug Saf 2015; 14(6): 839-44.
[http://dx.doi.org/10.1517/14740338.2015.1027681] [PMID: 25802019]
[130]
Bălănescu AR, Bojincă VC, Bojincă M, Donisan T, Bălănescu SM. Cardiovascular effects of methotrexate in immune-mediated inflammatory diseases. Exp Ther Med 2019; 17(2): 1024-9.
[PMID: 30679969]
[131]
Bartoloni E, Alunno A, Valentini V, et al. Targeting inflammation to prevent cardiovascular disease in chronic rheumatic diseases: myth or reality? Front Cardiovasc Med 2018; 5: 177.
[http://dx.doi.org/10.3389/fcvm.2018.00177] [PMID: 30619884]
[132]
Mangoni AA, Tommasi S, Zinellu A, et al. Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate. Drugs Context 2018; 7212557
[http://dx.doi.org/10.7573/dic.212557] [PMID: 30459819]
[133]
Ronda N, Greco D, Adorni MP, et al. Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism. Arthritis Rheumatol 2015; 67(5): 1155-64.
[http://dx.doi.org/10.1002/art.39039] [PMID: 25605003]
[134]
Reiss AB, Carsons SE, Anwar K, et al. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum 2008; 58(12): 3675-83.
[http://dx.doi.org/10.1002/art.24040] [PMID: 19035488]
[135]
Charles-Schoeman C, Yin Lee Y, Shahbazian A, et al. Improvement of high-density lipoprotein function in patients with early rheumatoid arthritis treated with methotrexate monotherapy or combination therapies in a randomized controlled trial. Arthritis Rheumatol 2017; 69(1): 46-57.
[http://dx.doi.org/10.1002/art.39833] [PMID: 27483410]
[136]
Zimmerman MC, Clemens DL, Duryee MJ, et al. Direct antioxidant properties of methotrexate: Inhibition of malondialdehyde-acetaldehyde-protein adduct formation and superoxide scavenging. Redox Biol 2017; 13: 588-93.
[http://dx.doi.org/10.1016/j.redox.2017.07.018] [PMID: 28803127]
[137]
Hjeltnes G, Hollan I, Førre O, et al. Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor. Clin Exp Rheumatol 2013; 31(3): 415-21.
[PMID: 23465067]
[138]
MacMullan PA, Madigan AM, Paul N, et al. Sulfasalazine and its metabolites inhibit platelet function in patients with inflammatory arthritis. Clin Rheumatol 2016; 35(2): 447-55.
[http://dx.doi.org/10.1007/s10067-014-2769-x] [PMID: 25253538]
[139]
Karimifar M, Sepehrifar MS, Moussavi H, et al. The effects of conventional drugs in the treatment of rheumatoid arthritis on the serum lipids. J Res Med Sci 2018; 23: 105.
[PMID: 30693040]
[140]
van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006; 8(5): R151.
[http://dx.doi.org/10.1186/ar2045] [PMID: 16984661]
[141]
Tam HW, Yeo KJ, Leong PY, et al. Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: A nationwide population-based retrospective cohort study. Int J Rheum Dis 2017; 20(3): 363-70.
[http://dx.doi.org/10.1111/1756-185X.12986] [PMID: 27943609]
[142]
Serelis J, Panagiotakos DB, Mavrommati M, Skopouli FN. Cardiovascular disease is related to hypertension in patients with rheumatoid arthritis: a greek cohort study. J Rheumatol 2011; 38(2): 236-41.
[http://dx.doi.org/10.3899/jrheum.100564] [PMID: 21078723]
[143]
Solomon DH, Avorn J, Katz JN, et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54(12): 3790-8.
[http://dx.doi.org/10.1002/art.22255] [PMID: 17136752]
[144]
Rozman B, Praprotnik S, Logar D, et al. Leflunomide and hypertension. Ann Rheum Dis 2002; 61(6): 567-9.
[http://dx.doi.org/10.1136/ard.61.6.567] [PMID: 12006342]
[145]
Kerr G, Aujero M, Richards J, et al. Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications. Arthritis Care Res (Hoboken) 2014; 66(11): 1619-26.
[http://dx.doi.org/10.1002/acr.22341] [PMID: 24692402]
[146]
Morris SJ, Wasko MC, Antohe JL, et al. Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2011; 63(4): 530-4.
[http://dx.doi.org/10.1002/acr.20393] [PMID: 21452265]
[147]
Rempenault C, Combe B, Barnetche T, et al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2018; 77(1): 98-103.
[http://dx.doi.org/10.1136/annrheumdis-2017-211836] [PMID: 28970215]
[148]
Li HZ, Xu XH, Lin N, Lu HD. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2019; 78(3)e21
[http://dx.doi.org/10.1136/annrheumdis-2018-213157] [PMID: 29453218]
[149]
Dixon WG, Symmons DP. What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. Ann Rheum Dis 2007; 66(9): 1132-6.
[http://dx.doi.org/10.1136/ard.2006.063867] [PMID: 17251223]
[150]
Low AS, Symmons DP, Lunt M, et al. Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis 2017; 76(4): 654-60.
[http://dx.doi.org/10.1136/annrheumdis-2016-209784] [PMID: 28073800]
[151]
Nurmohamed M, Choy E, Lula S, Kola B, DeMasi R, Accossato P. The impact of biologics and tofacitinib on cardiovascular risk factors and outcomes in patients with rheumatic disease: a systematic literature review. Drug Saf 2018; 41(5): 473-88.
[http://dx.doi.org/10.1007/s40264-017-0628-9] [PMID: 29318514]
[152]
Daïen CI, Fesler P, du Cailar G, et al. Etanercept normalises left ventricular mass in patients with rheumatoid arthritis. Ann Rheum Dis 2013; 72(6): 881-7.
[http://dx.doi.org/10.1136/annrheumdis-2012-201489] [PMID: 22872022]
[153]
Klarenbeek NB, van der Kooij SM, Huizinga TJ, et al. Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. Ann Rheum Dis 2010; 69(7): 1342-5.
[http://dx.doi.org/10.1136/ard.2009.124180] [PMID: 20472597]
[154]
Dulai R, Perry M, Twycross-Lewis R, Morrissey D, Atzeni F, Greenwald S. The effect of tumor necrosis factor-α antagonists on arterial stiffness in rheumatoid arthritis: a literature review. Semin Arthritis Rheum 2012; 42(1): 1-8.
[http://dx.doi.org/10.1016/j.semarthrit.2012.02.002] [PMID: 22475245]
[155]
Tam LS, Kitas GD, González-Gay MA. Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis? Rheumatology (Oxford) 2014; 53(6): 1108-19.
[http://dx.doi.org/10.1093/rheumatology/ket454] [PMID: 24501245]
[156]
Ursini F, Leporini C, Bene F, et al. Anti-TNF-alpha agents and endothelial function in rheumatoid arthritis: a systematic review and meta-analysis. Sci Rep 2017; 7(1): 5346.
[http://dx.doi.org/10.1038/s41598-017-05759-2] [PMID: 28706194]
[157]
Souto A, Salgado E, Maneiro JR, Mera A, Carmona L, Gómez-Reino JJ. Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol 2015; 67(1): 117-27.
[http://dx.doi.org/10.1002/art.38894] [PMID: 25303044]
[158]
Heslinga SC, Van Sijl AM, De Boer K, Van Halm VP, Nurmohamed MT. Tumor necrosis factor blocking therapy and congestive heart failure in patients with inflammatory rheumatic disorders: a systematic review. Curr Med Chem 2015; 22(16): 1892-902.
[http://dx.doi.org/10.2174/0929867322666150209160701] [PMID: 25666788]
[159]
Kotani K, Miyamoto M, Ando H. The effect of treatments for rheumatoid arthritis on endothelial dysfunction evaluated by flow-mediated vasodilation in patients with rheumatoid arthritis. Curr Vasc Pharmacol 2017; 15(1): 10-8.
[http://dx.doi.org/10.2174/1570161114666161013113457] [PMID: 27739363]
[160]
Benucci M, Bandinelli F, Damiani A, et al. Factors correlated with the improvement of endothelial dysfunction during Abatacept therapy in patients with rheumatoid arthritis. J Inflamm Res 2018; 11: 247-52.
[http://dx.doi.org/10.2147/JIR.S156822] [PMID: 29922080]
[161]
Ursini F, Russo E, Letizia Hribal M, et al. Abatacept improves whole-body insulin sensitivity in rheumatoid arthritis: an observational study. Medicine (Baltimore) 2015; 94(21)e888
[http://dx.doi.org/10.1097/MD.0000000000000888] [PMID: 26020396]
[162]
Kang EH, Jin Y, Brill G, et al. Comparative cardiovascular risk of abatacept and tumor necrosis factor inhibitors in patients with rheumatoid arthritis with and without diabetes mellitus: a multidatabase cohort study. J Am Heart Assoc 2018; 7(3)e007393
[http://dx.doi.org/10.1161/JAHA.117.007393] [PMID: 29367417]
[163]
Jin Y, Kang EH, Brill G, Desai RJ, Kim SC. Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease. J Rheumatol 2018; 45(9): 1240-8.
[http://dx.doi.org/10.3899/jrheum.170926] [PMID: 29764964]
[164]
Zhang J, Xie F, Yun H, et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis 2016; 75(10): 1813-8.
[http://dx.doi.org/10.1136/annrheumdis-2015-207870] [PMID: 26792814]
[165]
Generali E, Carrara G, Kallikourdis M, et al. Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept. Rheumatol Int 2019; 39(2): 239-43.
[http://dx.doi.org/10.1007/s00296-018-4196-9] [PMID: 30413926]
[166]
McInnes IB, Thompson L, Giles JT, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis 2015; 74(4): 694-702.
[http://dx.doi.org/10.1136/annrheumdis-2013-204345] [PMID: 24368514]
[167]
Kume K, Amano K, Yamada S, Hatta K, Ohta H, Kuwaba N. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. J Rheumatol 2011; 38(10): 2169-71.
[http://dx.doi.org/10.3899/jrheum.110340] [PMID: 21807781]
[168]
Castaneda S, Remuzgo-Martinez S, Lopez-Mejias R, et al. Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis. Clin Exp Rheumatol 2019; 37(3): 465-73.
[PMID: 30418124]
[169]
Fioravanti A, Tenti S, Bacarelli MR, et al. Tocilizumab modulates serum levels of adiponectin and chemerin in patients with rheumatoid arthritis: potential cardiovascular protective role of IL-6 inhibition. Clin Exp Rheumatol 2019; 37(2): 293-300.
[PMID: 30148441]
[170]
Jones G, Panova E. New insights and long-term safety of tocilizumab in rheumatoid arthritis. Ther Adv Musculoskelet Dis 2018; 10(10): 195-9.
[http://dx.doi.org/10.1177/1759720X18798462] [PMID: 30327685]
[171]
Kim SC, Solomon DH, Rogers JR, et al. No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study. Semin Arthritis Rheum 2018; 48(3): 399-405.
[http://dx.doi.org/10.1016/j.semarthrit.2018.03.012] [PMID: 29673963]
[172]
Xie F, Yun H, Levitan EB, Muntner P, Curtis JR. Tocilizumab and the risk for cardiovascular disease: a direct comparison among biologic disease-modifying antirheumatic drugs for rheumatoid arthritis patients. Arthritis Care Res 2019; 71(8): 1004-18.
[http://dx.doi.org/10.1002/acr.23737] [PMID: 30175897]
[173]
Singh S, Fumery M, Singh AG, et al. Comparative risk of cardiovascular events with biologic and synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res 2020; 72(4): 561-76.
[http://dx.doi.org/10.1002/acr.23875 ] [PMID: 30875456]
[174]
Charles-Schoeman C, Wicker P, Gonzalez-Gay MA, et al. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. Semin Arthritis Rheum 2016; 46(3): 261-71.
[http://dx.doi.org/10.1016/j.semarthrit.2016.05.014] [PMID: 27443588]
[175]
Kume K, Amano K, Yamada S, et al. Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study. Rheumatol Int 2017; 37(12): 2079-85.
[http://dx.doi.org/10.1007/s00296-017-3844-9] [PMID: 29030660]
[176]
Wang Z, Wang S, Wang Z, Yun T, Wang C, Wang H. Tofacitinib ameliorates atherosclerosis and reduces foam cell formation in apoE deficient mice. Biochem Biophys Res Commun 2017; 490(2): 194-201.
[http://dx.doi.org/10.1016/j.bbrc.2017.06.020] [PMID: 28601639]
[177]
Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 2008; 26(5)(Suppl. 51): S35-61.
[PMID: 19026144]
[178]
van den Hoek J, Boshuizen HC, Roorda LD, et al. Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study. Rheumatol Int 2017; 37(4): 487-93.
[http://dx.doi.org/10.1007/s00296-016-3638-5] [PMID: 28032180]
[179]
Ikdahl E, Rollefstad S, Wibetoe G, et al. Feasibility of cardiovascular disease risk assessments in rheumatology outpatient clinics: ex-periences from the nationwide NOCAR project. RMD Open 2018; 4(2) e000737
[http://dx.doi.org/10.1136/rmdopen-2018-000737] [PMID: 30305931]
[180]
Chodara AM, Wattiaux A, Bartels CM. Managing cardiovascular disease risk in rheumatoid arthritis: clinical updates and three strategic approaches. Curr Rheumatol Rep 2017; 19(4): 16.
[http://dx.doi.org/10.1007/s11926-017-0643-y] [PMID: 28361332]
[181]
Alemao E, Cawston H, Bourhis F, et al. Comparison of cardiovascular risk algorithms in patients with vs without rheumatoid arthritis and the role of C-reactive protein in predicting cardiovascular outcomes in rheumatoid arthritis. Rheumatology (Oxford) 2017; 56(5): 777-86.
[PMID: 28087832]
[182]
Navarini L, Margiotta DPE, Caso F, et al. Performances of five risk algorithms in predicting cardiovascular events in patients with Psoriatic Arthritis: An Italian bicentric study. PLoS One 2018; 13(10)e0205506
[http://dx.doi.org/10.1371/journal.pone.0205506] [PMID: 30308025]
[183]
Crowson CS, Gabriel SE, Semb AG, et al. Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries. Rheumatology (Oxford) 2017; 56(7): 1102-10.
[http://dx.doi.org/10.1093/rheumatology/kex038] [PMID: 28339992]
[184]
Ljung L, Ueda P, Liao KP, et al. Performance of the expanded cardiovascular risk prediction score for rheumatoid arthritis in a ge-ographically distant national register-based cohort: an external validation. RMD Open 2018; 4(2)e000771
[http://dx.doi.org/10.1136/rmdopen-2018-000771] [PMID: 30622736]
[185]
Wahlin B, Innala L, Magnusson S, et al. Performance of the expanded cardiovascular risk prediction score for rheumatoid arthritis is not superior to the ACC/AHA Risk Calculator. J Rheumatol 2019; 46(2): 130-7.
[http://dx.doi.org/10.3899/jrheum.171008] [PMID: 30275258]
[186]
van den Oever IAM, Heslinga M, Griep EN, et al. Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the implementation of cardiovascular risk management in rheumatoid arthritis project. Rheumatology (Oxford) 2017; 56(9): 1472-8.
[http://dx.doi.org/10.1093/rheumatology/kew497] [PMID: 28199724]
[187]
Bartels CM, Kind AJ, Everett C, Mell M, McBride P, Smith M. Low frequency of primary lipid screening among medicare patients with rheumatoid arthritis. Arthritis Rheum 2011; 63(5): 1221-30.
[http://dx.doi.org/10.1002/art.30239] [PMID: 21305507]
[188]
Jafri K, Bartels CM, Shin D, Gelfand JM, Ogdie A. Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: a population-based study. Arthritis Care Res 2017; 69(1): 51-7.
[http://dx.doi.org/10.1002/acr.23094] [PMID: 27696731]
[189]
England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ 2018; 361: k1036.
[http://dx.doi.org/10.1136/bmj.k1036] [PMID: 29685876]
[190]
Khoja SS, Almeida GJ, Chester Wasko M, Terhorst L, Piva SR. Association of light-intensity physical activity with lower cardiovascular disease risk burden in rheumatoid arthritis. Arthritis Care Res 2016; 68(4): 424-31.
[http://dx.doi.org/10.1002/acr.22711] [PMID: 26314559]
[191]
Metsios GS, Stavropoulos-Kalinoglou A, Veldhuijzen van Zanten JJ, et al. Individualized exercise improves endothelial function in patients with rheumatoid arthritis. Ann Rheum Dis 2014; 73(4): 748-51.
[http://dx.doi.org/10.1136/annrheumdis-2013-203291] [PMID: 23904472]
[192]
Veldhuijzen van Zanten JJCS, Sandoo A, Metsios GS, Stavropoulos-Kalinoglou A, Ntoumanis N, Kitas GD. Comparison of the effects of exercise and anti-TNF treatment on cardiovascular health in rheumatoid arthritis: results from two controlled trials. Rheumatol Int 2019; 39(2): 219-25.
[http://dx.doi.org/10.1007/s00296-018-4183-1] [PMID: 30421104]
[193]
Dattilo G, Borgia F, Guarneri C, et al. Cardiovascular risk in psoriasis: current state of the art. Curr Vasc Pharmacol 2019; 17(1): 85-91.
[http://dx.doi.org/10.2174/1570161115666171116163816] [PMID: 29149819]
[194]
Kristensen SL, McInnes IB, Sattar N. Psoriasis, psoriatic arthritis and cardiovascular risk: are we closer to a clinical recommendation? Ann Rheum Dis 2015; 74(2): 321-2.
[http://dx.doi.org/10.1136/annrheumdis-2014-206617] [PMID: 25429028]

Rights & Permissions Print Cite
Article Metrics
33
© 2024 Bentham Science Publishers | Privacy Policy